Bank of America just raised its EUR/USD forecast
In a recent transaction, Kevin J. McNamara, the President and CEO of Chemed Corp (NYSE:CHE), sold 1,000 shares of the company’s stock. The sale, which took place on March 31, 2025, was executed at a weighted average price of $615.33 per share, resulting in a total transaction value of $615,330. The transaction occurred as the stock trades near its 52-week high of $642.68, with InvestingPro data showing the company maintains a "GREAT" financial health score.
According to the filing, McNamara’s transactions were conducted at prices ranging from $610.33 to $619.45 per share. Following this sale, McNamara retains ownership of 101,679 shares in the company. Analyst targets for the stock range from $650 to $708, according to InvestingPro data, which offers 15+ additional investment insights for subscribers.
Chemed Corp, based in Cincinnati, Ohio, is a prominent player in the home health care services sector. With a market capitalization of $9.07 billion, the company has maintained dividend payments for 55 consecutive years and achieved a 7.4% revenue growth in the last twelve months. Discover more detailed analysis in the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Chemed Corporation reported its fourth-quarter 2024 earnings, revealing a strong performance with earnings per share of $6.83, surpassing the expected $6.78. The company’s revenue also exceeded projections, reaching $640 million compared to the anticipated $636.1 million. This growth was primarily driven by a 17.4% increase in the VITAS segment, despite a slight decline in Roto Rooter’s revenue. Chemed has provided guidance for full-year 2025 earnings per share to be between $24.95 and $25.45, up from $23.13 in 2024. Additionally, analysts have noted that Chemed’s stock was not subject to any upgrades or downgrades following these announcements. The company has also been expanding its operations, with VITAS recently opening a new program in Pasco County, Florida, and planning to enter Marion County soon. These recent developments indicate continued growth potential for Chemed, particularly in its VITAS Healthcare segment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.